Advances in ADT: A Guide for Urologists and APPs Webcast (2023)

Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: A Guide for Urologists (2023), a series of educational offerings to update urologists on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including a live course, on-demand webcast, and a podcast series. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion. 

ACKNOWLEDGEMENT

Independent educational grant support provided by:

  • Myovant Sciences LTD
  • Pfizer Inc. 

Target Audience

  • Urologists
  • APPs 

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify and treat a patient with new diagnosed M1 prostate cancer with ADT plus be able to offer additional therapies that extend survival.
  2. Analyze the risks and benefits of treatment for M1 HSPC, MO CRPC, and M1 CRPC. 
  3. Differentiate the clinical significance of GnRH agonists vs. GnRH antagonists and newer treatments that complement these options.
  4. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.
  5. Facilitate discussions with patients and caregivers regarding ADT and advanced prostate cancer treatment.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
02/08/2023
Course expires: 
02/08/2024
Rating: 
0

EDUCATION COUNCIL DISCLOSURES:

PDF icon Education Council Disclosures_2022.pdf

COI REVIEW WORKGROUP DISCLOSURES:

PDF iconCOI Review Work Group Disclosures_2023_0.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Course Director(s)

Kristen Scarpato, MD,FACS,MPH

has a financial relationship (Consultant or Advisor (Oncology)) with Optum;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Photocure;.
has a financial relationship (Consultant or Advisor (Oncology)) with CxBladder;.
Faculty(s)

Meredith Donahue, NP

has no relevant financial relationships to disclose at this time.

Alicia Morgans, MD

has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Progenics ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sanofi;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with BMS;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity:1.0 hours

Release Date: February, 2023
Expiration Date: February, 2024

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.